ZA200610561B - TC-83-derived alphavirus vectors, particles and methods - Google Patents

TC-83-derived alphavirus vectors, particles and methods

Info

Publication number
ZA200610561B
ZA200610561B ZA200610581A ZA200610561A ZA200610561B ZA 200610561 B ZA200610561 B ZA 200610561B ZA 200610581 A ZA200610581 A ZA 200610581A ZA 200610561 A ZA200610561 A ZA 200610561A ZA 200610561 B ZA200610561 B ZA 200610561B
Authority
ZA
South Africa
Prior art keywords
particles
derived
methods
alphavirus vectors
arps
Prior art date
Application number
ZA200610581A
Other languages
English (en)
Inventor
Jon O Rayner
Jonathan F Smith
Hubby Bolyn
Elizabeth A Reap
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphavax Inc filed Critical Alphavax Inc
Publication of ZA200610561B publication Critical patent/ZA200610561B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200610581A 2004-05-18 2006-12-15 TC-83-derived alphavirus vectors, particles and methods ZA200610561B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57221204P 2004-05-18 2004-05-18
PCT/US2005/017766 WO2005113782A1 (en) 2004-05-18 2005-05-18 Tc-83-derived alphavirus vectors, particles and methods

Publications (1)

Publication Number Publication Date
ZA200610561B true ZA200610561B (en) 2008-06-25

Family

ID=34970550

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610581A ZA200610561B (en) 2004-05-18 2006-12-15 TC-83-derived alphavirus vectors, particles and methods

Country Status (16)

Country Link
US (5) US20050266550A1 (xx)
EP (1) EP1751289B1 (xx)
JP (1) JP5065024B2 (xx)
CN (1) CN1989250B (xx)
AT (1) ATE420965T1 (xx)
AU (1) AU2005245956B2 (xx)
CA (1) CA2567254C (xx)
DE (1) DE602005012382D1 (xx)
DK (1) DK1751289T3 (xx)
ES (1) ES2321212T3 (xx)
IL (1) IL178917A (xx)
MX (1) MXPA06013124A (xx)
NZ (1) NZ550818A (xx)
PT (1) PT1751289E (xx)
WO (1) WO2005113782A1 (xx)
ZA (1) ZA200610561B (xx)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
DE602005012382D1 (de) 2004-05-18 2009-03-05 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
EP2061508B1 (en) 2006-09-12 2014-10-15 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
ES2746960T3 (es) 2006-09-12 2020-03-09 Alphavax Inc Partículas de replicón de alfavirus que codifican IL-12 como adyuvantes inmunológicos
ES2673823T3 (es) * 2006-11-03 2018-06-25 Alphavax, Inc. Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
EP2947149B1 (en) 2007-06-21 2018-02-28 Alphavax, Inc. Alphavirus replicon particles for use in vaccination
WO2009048633A2 (en) * 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
WO2009051707A1 (en) * 2007-10-15 2009-04-23 Duke University Vaccine vectors
US20100010888A1 (en) * 2008-07-14 2010-01-14 Richard Maertz Methods and systems for offering purchase incentives
EP2370584B1 (en) 2008-12-01 2014-11-05 Alphavax, Inc. Use of microRNAs to control virus helper nucleic acids
US20120128714A1 (en) 2009-04-08 2012-05-24 Wolchok Jedd D Alphavirus Replicon Particles Expressing TRP2
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
JP6061849B2 (ja) 2010-07-06 2017-01-18 ノバルティス アーゲー 自己複製ｒｎａ分子についてのビリオン様送達粒子
DK2591114T3 (en) 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
EP3243526B1 (en) 2010-07-06 2019-11-27 GlaxoSmithKline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
WO2012006293A1 (en) 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
LT4066856T (lt) 2010-08-31 2023-01-25 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
CN103179989A (zh) * 2010-08-31 2013-06-26 诺华有限公司 用于递送编码免疫原的rna的小脂质体
RU2577983C2 (ru) 2010-08-31 2016-03-20 Новартис Аг Липиды, подходящие для липосомной доставки кодирующей белок рнк
CA2814386C (en) * 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
US10004797B2 (en) * 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
JP2014520806A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
LT2750707T (lt) 2011-08-31 2019-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
RU2015132962A (ru) 2013-01-10 2017-02-14 Новартис Аг Иммуногенные композиции на основе вируса гриппа и их применение
BR112015023513A2 (pt) 2013-03-15 2017-07-18 Glaxosmithkline Biologicals Sa métodos de purificação de rna
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10842859B2 (en) 2014-03-25 2020-11-24 Yale University Uses of parasite macrophage migration inhibitory factors
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106687590B (zh) 2014-09-11 2021-08-03 Vlp治疗公司 黄热病毒病毒样颗粒
WO2017123652A1 (en) 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same
BE1024796B9 (fr) 2016-06-02 2019-01-08 Glaxosmithkline Biologicals Sa Constructions antigeniques du virus zika
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
BE1025121B1 (fr) 2016-11-17 2018-11-05 Glaxosmithkline Biologicals Sa Constructions antigeniques du virus zika
AU2017372731B2 (en) 2016-12-05 2024-05-23 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
US20200121774A1 (en) * 2017-04-19 2020-04-23 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
WO2019086646A1 (en) 2017-11-06 2019-05-09 Intervet International B.V. Feline leukemia virus vaccine
BR112020008240A2 (pt) 2017-11-06 2020-11-17 Intervet International B.V. vacina contra o vírus da raiva
US11229699B2 (en) 2017-11-06 2022-01-25 Intervet Inc. Feline calicivirus vaccine
US11311616B2 (en) 2017-11-06 2022-04-26 Intervet Inc. Feline leukemia virus vaccine
MX2020005584A (es) 2017-12-04 2020-09-14 Intervet Int Bv Vacunacion con particulas de replicon y adyuvante oleoso.
EP3720489A1 (en) 2017-12-04 2020-10-14 Intervet International B.V. Canine lyme disease vaccine
AU2018380582A1 (en) 2017-12-08 2020-05-07 Intervet International B.V. Feline calicivirus vaccine
CA3080087A1 (en) 2017-12-15 2019-06-20 Intervet International B.V. Multivalent feline vaccine
EP3727444A1 (en) 2017-12-18 2020-10-28 Intervet International B.V. Swine influenza a virus vaccine
MX2020007675A (es) * 2018-01-19 2020-09-14 Janssen Pharmaceuticals Inc Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante.
JP2021534182A (ja) 2018-08-17 2021-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物及びその使用
EP3897710A1 (en) 2018-12-20 2021-10-27 Intervet International B.V. Prime-boost vaccination regimen
CN109784705B (zh) * 2019-01-02 2021-07-02 中国石油天然气股份有限公司 预测产油量的方法、装置及存储介质
KR20220035457A (ko) 2019-07-21 2022-03-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 치료 바이러스 백신
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
US11730799B2 (en) 2019-10-18 2023-08-22 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Transient temperature-based delivery of nucleic acids and proteins to cells and tissues
TW202200605A (zh) 2020-03-09 2022-01-01 美商亞克圖羅斯醫療公司 冠狀病毒疫苗組成物和方法
US20230364219A1 (en) 2020-04-16 2023-11-16 Glaxosmithkline Biologicals Sa Sars cov-2 spike protein construct
WO2021210686A1 (en) * 2020-04-17 2021-10-21 Vlp Therapeutics, Inc. Coronavirus vaccine
EP4149532A1 (en) * 2020-05-11 2023-03-22 Intervet International B.V. Feline severe acute respiratory syndrome coronavirus 2 vaccine
EP4161570A1 (en) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Modified betacoronavirus spike proteins
WO2021255225A1 (en) 2020-06-19 2021-12-23 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
EP4168428A1 (en) 2020-06-19 2023-04-26 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct encoding antigens of specific virus lineages
WO2021255222A1 (en) 2020-06-19 2021-12-23 Intervet International B.V. Swine influenza a virus vaccine comprising two distinct rna replicon particles
US20230265130A1 (en) 2020-06-19 2023-08-24 Intervet Inc. Swine influenza a virus vaccine comprising a nucleic acid construct having a specific order of genes
MX2022016105A (es) 2020-06-19 2023-03-08 Ziphius Vaccines Vacuna autoamplificadora de arn del sars-cov-2.
US20230256090A1 (en) 2020-06-29 2023-08-17 Glaxosmithkline Biologicals Sa Adjuvants
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
BR112023004123A2 (pt) 2020-09-07 2023-04-04 Intervet Int Bv Vacina de haste da ha para alvos positivos de anticorpos de ha
TW202233232A (zh) 2020-11-06 2022-09-01 法商賽諾菲公司 遞送mRNA疫苗的脂質奈米顆粒
EP4243864A1 (en) 2020-11-12 2023-09-20 Intervet International B.V. Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof
WO2022137128A2 (en) 2020-12-23 2022-06-30 Glaxosmithkline Biologicals Sa Self-amplifying messenger rna
EP4032546A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Therapeutic viral vaccine
EP4313152A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
WO2022248353A1 (en) 2021-05-24 2022-12-01 Glaxosmithkline Biologicals Sa Adjuvants
AU2022294274A1 (en) 2021-06-18 2024-02-01 Sanofi Multivalent influenza vaccines
EP4387596A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
CN118043466A (zh) 2021-09-03 2024-05-14 葛兰素史克生物有限公司 自扩增信使核糖核酸中核苷酸碱基的取代
WO2023072805A1 (en) 2021-10-25 2023-05-04 Intervet International B.V. A vaccine for the protection of piglets against swine influenza a virus infection
AU2022381685A1 (en) 2021-11-02 2024-05-16 Ziphius Nv Lipid nanoparticles for oligonucleotide delivery
AU2022381463A1 (en) 2021-11-02 2024-05-16 Ziphius Nv Lipid nanoparticles for oligonucleotide delivery
WO2023078954A1 (en) 2021-11-02 2023-05-11 Ziphius Vaccines Nv Lipid nanoparticles for oligonucleotide delivery
US20230302112A1 (en) 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
US11730804B1 (en) * 2022-04-13 2023-08-22 Replicate Bioscience, Inc. Compositions and methods for the prevention and treatment of rabies virus infection
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
WO2024044108A1 (en) 2022-08-22 2024-02-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against coronaviruses
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US20020102273A1 (en) * 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
AU6172194A (en) * 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
CA2158937C (en) 1993-09-15 2006-01-03 Thomas W. Dubensky, Jr. Recombinant alphavirus vectors
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000514290A (ja) * 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
US5827658A (en) * 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5726022A (en) * 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
EP1707631A3 (en) * 1996-11-20 2006-12-27 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) * 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
ATE457176T1 (de) 1998-04-08 2010-02-15 Univ North Carolina Krebsimpfstoff enthaltend alphavirusrepliconpartikeln
US6146874A (en) * 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
WO2000002524A2 (en) * 1998-07-10 2000-01-20 U.S. Army Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
JP3585778B2 (ja) * 1998-09-25 2004-11-04 株式会社白子 海苔の酵素分解組成物およびその用途
CA2345440A1 (en) * 1998-10-05 2000-04-13 Charles A. Nicolette Genes differentially expressed in cancer cells to design cancer vaccines
CA2359013C (en) 1998-12-31 2011-02-01 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
JP4637368B2 (ja) 1999-04-14 2011-02-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法
DE60027768T2 (de) 1999-08-17 2007-04-05 Purdue Research Foundation, West Lafayette Behandlung von metastatischer krankheit
JP2003512077A (ja) * 1999-10-26 2003-04-02 インターナショナル エイズ バクシーン イニシアティブ アルファウイルスレプリコンを発現する侵襲性細菌
DE60135983D1 (de) * 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002003917A2 (en) * 2000-07-07 2002-01-17 Alphavax, Inc. Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
EP2198882A3 (en) * 2001-01-12 2010-10-13 Novartis Vaccines and Diagnostics, Inc. Nucleic acid mucosal immunization
WO2002099035A2 (en) * 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
US6605947B2 (en) * 2001-10-03 2003-08-12 Yi-Chia Liao Cup shape sensible container for detecting liquid property
JP3857195B2 (ja) * 2002-07-09 2006-12-13 株式会社東芝 距離継電装置
DK1590451T3 (en) * 2002-12-13 2015-12-14 Alphavax Inc ALPHAVIRUS PARTICLES AND PROCEDURES FOR MANUFACTURING
JP4991108B2 (ja) * 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
NZ542353A (en) 2003-03-20 2008-07-31 Alphavax Inc Improved alphavirus replicons and helper constructs
US7419674B2 (en) * 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
DE602005012382D1 (de) 2004-05-18 2009-03-05 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines

Also Published As

Publication number Publication date
EP1751289B1 (en) 2009-01-14
US20140205629A1 (en) 2014-07-24
CA2567254A1 (en) 2005-12-01
AU2005245956A1 (en) 2005-12-01
EP1751289A1 (en) 2007-02-14
US20160348132A1 (en) 2016-12-01
AU2005245956B2 (en) 2011-05-19
NZ550818A (en) 2009-09-25
ES2321212T3 (es) 2009-06-03
PT1751289E (pt) 2009-03-31
US20050266550A1 (en) 2005-12-01
US9079943B2 (en) 2015-07-14
US8709441B2 (en) 2014-04-29
DK1751289T3 (da) 2009-05-11
US20110027306A1 (en) 2011-02-03
ATE420965T1 (de) 2009-01-15
CA2567254C (en) 2012-03-13
JP5065024B2 (ja) 2012-10-31
US10570416B2 (en) 2020-02-25
JP2007537761A (ja) 2007-12-27
DE602005012382D1 (de) 2009-03-05
WO2005113782A1 (en) 2005-12-01
US9441247B2 (en) 2016-09-13
IL178917A0 (en) 2007-03-08
CN1989250B (zh) 2013-11-20
IL178917A (en) 2010-11-30
MXPA06013124A (es) 2007-05-23
US20150299728A1 (en) 2015-10-22
CN1989250A (zh) 2007-06-27

Similar Documents

Publication Publication Date Title
ZA200610561B (en) TC-83-derived alphavirus vectors, particles and methods
DK1635863T3 (da) Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
AU2001275191A1 (en) Method for the purification of alphavirus replicon particles
SG156666A1 (en) Vaccines against japanese encephalitis virus and west nile virus
MY178870A (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
MX2012004339A (es) Control de perfil de pitadas.
DE602005014628D1 (de) Embolie-teilchen
WO2006073431A3 (en) Avipox recombinants expressing foot and mouth disease virus genes
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
SG163572A1 (en) Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
MX2009001778A (es) Peptidos pcpa inmunogenicos y usos de los mismos.
EP2525816A4 (en) PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
MX2007005156A (es) Trehalosa y/o isomaltulosa como excipiente para formulaciones de aroma secas.
WO2006041897A3 (en) Chimeric vectors
AP2005003234A0 (en) Lectin compositions and methods for modulating an immune response to an antigen.
WO2007081848A3 (en) Activation of hcv-specific t cells
NZ631012A (en) Compositions and methods for live, attenuated alphavirus formulations
WO2012045063A3 (en) Flavivirus domain iii vaccine
UA107659C2 (en) Foaming coffee compositions
WO2014152092A3 (en) Methods and compositions for modulating regulatory t cell function
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
EP1593738A4 (en) VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT
WO2003084988A3 (de) Cd4+ t-lymphozyten spezifische hepatitis c virus-epitope
WO2005026316A8 (en) Alphavirus vaccines
Ransom Dan Ransom Photographs